IDH2 has been shown to reduce and convert α‐ketoglutarate to citric acid, a metabolic pathway that increases in factors such as impaired mitochondrial respiration, hypoxic environments, or cancer cell metabolism, and is considered a key enzyme in the rTCA cycle (Heinz et al. 2022). The gene discussed is IDH2; the disease is cancer.